Onglyza receives positive opinion in Europe for type 2 diabetes
Published at: www.pharmabiz.com
-
July 1, 2009
Saxagliptin, perhaps the DPP-IV inhibitor with the best name is on the verge of being granted a license in Europe. This will be the third DPP-IV inhibitor available for use in Europe, and is likely to have the same blip in use followed by a prolonged lull whilst the wait for long-term safety data takes place. Like all new drugs for type 2 diabetes mellitus, it has the magic 1% HbA1c reduction, and short-term safety data, but like all the rest from SU's to insulin the long-term data is modest, scant or lacking. As Lantus takes a hit from authors suggesting a cancer link, the time for novel agents which are at least as good as once daily insulin is here. Without evidence of durable effect however, is Saxagliptin or its cousins the answer. Unfortunately the wait might betoo long to bear.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software